54th Child Neurology Society Annual Meeting in October at the Charlotte Convention Center Coverage

Review 7: Novel Biomarkers Predict Treatment Response in SCN1A-Related Epilepsies

Groundbreaking research from Chen and colleagues at Boston Children’s Hospital identifies electroencephalographic biomarkers that predict treatment response in SCN1A-related epilepsies, potentially revolutionizing personalized medicine approaches for Dravet syndrome. The prospective cohort study, presented at the Child Neurology Society Annual Meeting, analyzed quantitative EEG features from 156 patients with confirmed SCN1A mutations before initiating new anti-seizure medications.

The investigators employed advanced signal processing techniques to extract spectral power, connectivity measures, and entropy indices from routine and prolonged EEG recordings. Machine learning algorithms integrated these features with clinical variables including age, seizure burden, and mutation type to develop predictive models for treatment response. Patients were followed for minimum six months after medication initiation to assess seizure reduction and tolerability outcomes.

The predictive model achieved 81% accuracy in identifying responders to sodium channel blockers, historically contraindicated in Dravet syndrome but potentially beneficial in specific SCN1A variant subgroups. Theta-band coherence patterns distinguished patients likely to respond to stiripentol versus cannabidiol with 77% accuracy. Gamma power ratios predicted fenfluramine response with 83% sensitivity and 79% specificity. These biomarkers remained robust across age groups and disease severities.

The research introduces paradigm-shifting precision medicine capabilities for SCN1A-related epilepsies. Rather than empirical medication trials, clinicians could utilize EEG biomarkers to select optimal therapies from treatment initiation. This approach could minimize exposure to ineffective medications, reduce time to seizure control, and prevent adverse events from contraindicated drugs. Validation studies are underway to confirm these findings across diverse populations and clinical settings.

Reference: Chen L, Wu T, Patel S, et al. Quantitative EEG Biomarkers for Predicting Anti-Seizure Medication Response in SCN1A-Related Epileptic Encephalopathies. Presented at: Child Neurology Society Annual Meeting; October 2025; Charlotte, NC.

Review 8: Temperature-Sensitive Seizure Prevention Protocol Reduces Hospitalizations in Dravet Syndrome

A quality improvement initiative by Roberts and colleagues from Philadelphia demonstrates significant reduction in seizure-related hospitalizations through implementation of a proactive temperature management protocol for Dravet syndrome patients. The study, presented at the Child Neurology Society Annual Meeting, evaluated outcomes in 73 patients following systematic deployment of preventive cooling strategies and rescue medication algorithms across multiple care settings.

The comprehensive protocol incorporated continuous temperature monitoring devices, prophylactic antipyretic regimens, environmental cooling strategies, and staged rescue medication plans triggered by specific temperature thresholds. Families received intensive education including video training, written action plans, and 24-hour nurse hotline access. School personnel and emergency responders received targeted training on Dravet-specific seizure triggers and management approaches. Implementation occurred through phased rollout with iterative refinement based on family feedback.

Results demonstrated 67% reduction in emergency department visits and 58% decrease in hospital admissions over 18 months compared to historical controls. Mean monthly seizure frequency decreased from 12.3 to 7.8 episodes. Prolonged seizures requiring rescue medication decreased by 71%. Family confidence scores for seizure management improved from 4.2 to 8.1 on validated scales. Cost analysis revealed average savings of $47,000 per patient annually through prevented hospitalizations.

The protocol’s success highlights the impact of proactive, trigger-focused management in Dravet syndrome. Temperature dysregulation represents a modifiable risk factor amenable to systematic intervention. This quality improvement model demonstrates feasibility of complex care coordination across home, school, and medical settings. Broader implementation could substantially reduce morbidity and healthcare utilization while empowering families with actionable management strategies.

Reference: Roberts M, Johnson A, Williams K, et al. Implementation and Outcomes of a Comprehensive Temperature-Sensitive Seizure Prevention Protocol in Dravet Syndrome. Presented at: Child Neurology Society Annual Meeting; October 2025; Charlotte, NC.